Robert Lentz, MD
Medical Oncology · Aurora, CONPI 1881056323
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,360 of the $8,192 with a category attached, or 77.6%. 6 manufacturers reported payments, led by Boehringer Ingelheim International GmbH at 45.2% of the total. Reporting peaked in 2024 at $6,736 and has fallen 98.3% since, to $118 in 2025.
Across 18 payments — averaging $455.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim International GmbH$4K
- Merck$2K
- Boehringer Ingelheim$1K
- AstraZeneca$643
- Intera Oncology, Inc$162
- Jazz Pharmaceuticals Inc.$95
Across 54 payments — averaging $61,902 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$2.9M
- Boehringer Ingelheim$213K
- AstraZeneca$161K
- Boehringer Ingelheim Pharma GmbH & Co.kg$20K
- Boehringer Ingelheim International GmbH$598
What the payments were for
- Consulting fees$6,36078%
- Travel & lodging$1,06713%
- Food & beverage$7659%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim International GmbH | 1 | $3,700 |
| Merck | 4 | $2,361 |
| Boehringer Ingelheim | 9 | $1,232 |
| AstraZeneca | 2 | $643 |
| Intera Oncology, Inc | 1 | $162 |
| Jazz Pharmaceuticals Inc. | 1 | $95 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,192 in reported general payments places this provider in the 70th percentile of 96 medical oncology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 11 | $24,202 |
| EliquisApixaban | 11 | $8,653 |
| Ondansetron Hcl | 29 | $732 |
| Prochlorperazine Maleate | 32 | $349 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 17 | $188 |
| Oxycodone Hcl | 13 | $123 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Aurora
- David CamidgeAurora$648K
- Paul BunnAurora$354K
- Sapna PatelAurora$186K
- Sunnie KimAurora$81K
- Virginia BorgesAurora$68K
- Erin SchenkAurora$63K
- Karl LewisAurora$62K
- Jose PachecoAurora$50K
- Leonard GlodeAurora$49K
- Robert DoebeleAurora$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.